Table 1.
Clinical characteristics of the subjects in each set.
| Training Set | Test Set | ||||||
|---|---|---|---|---|---|---|---|
| Variables | HCC | Cirrhosis | Healthy Controls | p-Value | HCC | Cirrhosis | p-Value |
| (n = 53) | (n = 47) | (n = 50) | (n = 82) | (n = 80) | |||
| Age, years | 59.0 (54.5–65.5) | 60.0 (55.0–65.0) | 51.0 (38.8–58.3) | 0.73 | 62.0 (55.0–68.3) | 59.0 (52.0–66.0) | 0.09 |
| Male | 35 (66.0%) | 34 (72.3%) | 25 (50.0%) | 1.00 | 57 (69.5%) | 54 (67.5%) | 1.00 |
| Etiology of liver disease | |||||||
| 0.002 | 0.03 | ||||||
| HBV | 53 (100.0%) | 39 (83.0%) | - | 51 (62.1%) | 55 (68.8%) | ||
| HCV | 0 | 6 (12.8%) | - | 13 (15.9%) | 3 (3.8%) | ||
| Non-viral | 0 | 2 (4.2%) | - | 18 (22.0%) | 22 (27.5%) | ||
| Child-Pugh class | 0.10 | 1.00 | |||||
| A | 52 (98.1%) | 42 (89.4%) | - | 78 (95.1%) | 76 (95.0%) | ||
| B | 1 (1.9%) | 5 (10.6%) | - | 4 (3.7%) | 4 (5.0%) | ||
| α-fetoprotein, ng/mL, median (IQR) | 6.2 (3.9–21.3) | 2.8 (2.2–5.6) | 1.4 (1.0–2.0) | <0.001 | 10.3 (4.2–33.6) | 3.3 (2.1–4.9) | <0.001 |
| BCLC stage | |||||||
| Very early | 28 (52.8%) | 46 (56.1%) | |||||
| Early | 25 (47.2%) | 36 (43.9%) | |||||
Data are presented as medians with interquartile ranges (IQRs) or numbers (%), unless otherwise indicated. AJCC, the American Joint Committee on Cancer; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer staging system; HBV, hepatitis B virus; HCV, hepatitis C virus.